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Increasing antimicrobial resistance of Neisseria gon-
orrhoeae, particularly to third-generation cephalo-
sporins, has been reported in many countries. We 
examined the susceptibility (determined by Etest 
and evaluated using the breakpoints of the European 
Committee on Antimicrobial Susceptibility Testing) 
of 434 N. gonorrhoeae isolates collected from 107 
female and 327 male patients in Stuttgart, south-west 
Germany, between 2004 and 2015. During the study 
period, high proportions of isolates were resistant to 
ciprofloxacin (70.3%), tetracycline (48.4%; increas-
ing from 27.5% in 2004/2005 to 57.7% in 2014/2015; 
p = 0.0002) and penicillin (25.6%). The proportion of 
isolates resistant to azithromycin was low (5.5%) but 
tended to increase (p = 0.08). No resistance and sta-
ble minimum inhibitory concentrations were found for 
cefixime, ceftriaxone, and spectinomycin. High-level 
resistance was found for ciprofloxacin (39.6%) and 
tetracycline (20.0%) but not for azithromycin; 16.3% 
of the isolates produced betalactamase. Thus, cepha-
losporins can still be used for the treatment of gon-
orrhoea in the study area. To avoid further increasing 
resistance to azithromycin, its usage should be limited 
to patients allergic to cephalosporins, or (in combi-
nation with cephalosporins) to patients for whom no 
susceptibility testing could be performed or those co-
infected with chlamydiae. 
Introduction
Numbers of gonorrhoea cases have increased, and the 
World Health Organization has estimated 106 million 
new cases in adults worldwide for 2008, which was 
21% higher than numbers for 2005 [1]. At the same time, 
rising rates of antimicrobial resistance of its causative 
agent, Neisseria gonorrhoeae, have been reported in 
many parts of the world including Europe, even against 
the third-generation cephalosporins, cefixime and cef-
triaxone [2,3]. For this reason, cefixime alone is no 
longer recommended as single-drug treatment for gon-
orrhoea in Europe or the United States [4,5].
The European Gonococcal Antimicrobial Surveillance 
Programme (EURO-GASP) was established by 12 
European countries in 2004 in response to the emerg-
ing antimicrobial resistance of N. gonorrhoeae, as part 
of the European Surveillance of Sexually Transmitted 
Infections Project [6]. In 2016, EURO-GASP has par-
ticipation from laboratories from 21 European Union/
European Economic Area countries, which regularly 
report gonorrhoea susceptibility testing results and 
epidemiological surveillance data, and submit gono-
coccal isolates for centralised testing or participate 
in decentralised testing. Since 2009, EURO-GASP has 
been coordinated by the European Centre for Disease 
Prevention and Control (ECDC). Resistance data have 
been published regularly and in a timely manner [7,8], 
but the numbers of isolates tested per country are 
relatively low (between 10 and 251 in 2011 [8]) and 
therefore most likely not representative of the epide-
miological situation of the individual countries.
As cases of gonorrhoea or antimicrobial resistance 
patterns of N. gonorrhoeae isolates are not subject to 
reporting in Germany, data regarding current antimi-
crobial susceptibility and its development over time are 
scarce. Only three individual studies have addressed 
this issue in the past 10 years. Abraham et al. ana-
lysed 50 isolates collected between 2001 and 2010 in 
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Dresden, Saxony [9], while Horn and colleagues have 
reported the results of a nationwide surveillance study 
conducted by the Paul-Ehrlich-Society of Chemotherapy 
in 2010/2011 in which 213 isolates submitted by 23 
laboratories were analysed [10]. Additionally, minimum 
inhibitory concentrations (MICs) of selected antibiotics 
for 65 N. gonorrhoeae isolates collected in 2004/2005 
in southern Germany have been reported [11]. None of 
these studies has reported cephalosporin-resistant N. 
gonorrhoeae isolates. Data from EURO-GASP, however, 
have provided evidence for the presence of cephalo-
sporin-resistant N. gonorrhoeae isolates in Germany, 
too [7,8]; in fact, an Austrian patient with a cefixime-
resistant N. gonorrhoeae isolate acquired his infection 
in Munich, south Germany [12].
To gain more information on the antimicrobial suscep-
tibility of N. gonorrhoeae in Germany and elucidate 
possible changes in antimicrobial resistance occur-
ring over time, we analysed the susceptibility patterns 
of all N. gonorrhoeae isolates identified and tested in 
our laboratory between 2004 and 2015 (n = 434). Since 
age and sex have been identified as risk factors for 
harbouring antimicrobial-resistant N. gonorrhoeae iso-
lates [13,14], we additionally analysed our data regard-
ing these parameters. Unfortunately, the study design 
chosen did not provide information regarding other 
possible risk factors, e.g. working as professional sex 
worker or being a man who has sex with men (MSM).
Methods
Bacterial isolates 
Between July 2004 and March 2015, 434 bacterial iso-
lates were grown from swabs obtained from patients 
aged 16 years and over living in the greater Stuttgart 
area (a radius of around 50 km from Stuttgart city cen-
tre). Although difficult to estimate because N. gonor-
rhoeae is not mandatorily notifiable, the number of 
isolates tested may correspond to 30–70% of all iso-
lates detected in that area within the period of time 
indicated. The samples were mainly submitted by 
private practitioners (primarily urologists, internists, 
dermatologists, and gynaecologists). For 284 (65.4%) 
patients, further samples (swabs or urine) had been 
submitted for the detection of Chlamydia trachomatis 
by PCR. Based on these laboratory results, 36 (12.7%) 
patients were co-infected with C. trachomatis while 
248 (87.3%) were C. trachomatis-negative.
Gram-negative, oxidase-positive diplococci were iden-
tified biochemically as N. gonorrhoeae by using the API 
or the Vitek 2 system (both bioMerieux, Marcy-l Etoile, 
France). Isolates were subjected immediately to antimi-
crobial susceptibility testing and subsequently stored 
at –70 °C for future analyses.
Susceptibility testing
Briefly, bacterial inoculums were prepared in sterile 
saline at 0.5 McFarland standard and tested against 
the antibiotics indicated by using the Etest system (AB 
Biodisk, Solna, Sweden) on Mueller-Hinton chocolate 
agar, except for testing of azithromycin, for which a 
chocolate GC II agar with IsoVitaleX was used (both, 
BD Diagnostic Systems, Heidelberg, Germany) [11]. 
Plates were incubated at 35–36.5  °C and 5% CO2 for 
20–24 hours. Betalactamase production was assessed 
by using nitrocefin disks (BD Diagnostic Systems). 
The ATCC N. gonorrhoeae strain 49226 was used as 
an internal control. Susceptibility was interpreted 
according to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) and Clinical and 
Laboratory Standards Institute (CLSI) breakpoints 
[15,16].
Statistical analyses
Data were statistically analysed by using GraphPad 
Prism version 6.0a for Mac OS X. Data on antibiotic 
resistance, patients’ sex, or specialisation of refer-
ring practitioners were analysed using the two-tailed 
Fisher’s exact test. Data regarding age were ana-
lysed using the Mann–Whitney U-test. To elucidate 
potential changes in the antibiotic susceptibility in N. 
gonorhoeae isolates over time, data also were ana-
lysed for two different periods: July 2004 to December 
2009 and January 2010 to March 2015, as well as for 
two-year periods. Differences were considered statis-
tically significant at p < 0.05. Trends were defined as 
p-values between 0.05 and 0.1.
Figure 1
Percentages of Neisseria gonorrhoeae isolates resistant to 






























































Antimicrobial susceptibility of Neisseria gonorrhoeae isolates to (A) penicillin G, (B) cefixime, (C) ceftriaxone, (D) 
azithromycin, (E) ciprofloxacin, (F) tetracycline and (G) spectinomycin, south-west Germany, July 2004 to December 2015 
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The median age of the patients was 33 years (range: 
16–76), 107 (24.7%) were female and 327 (75.3%) were 
male. Analysis of antimicrobial susceptibility of the 
isolates to standard antibiotics revealed high propor-
tions of intermediate or resistant isolates for penicillin 
(90.6%), ciprofloxacin (70.5%), and tetracycline (68.9%) 
with lower proportions for azithromycin (26.5%; Table 
1). No resistance to cefixime, ceftriaxone, or spectin-
omycin was detected. Thirty-one isolates (7.1%) were 
susceptible to all antimicrobials tested.
High-level plasmid-mediated resistance to tetracycline 
(≥ 16 mg/L) was seen in 87 (20.0%) isolates whereas 
172 (39.6%) isolates expressed high-level resistance 
to ciprofloxacin (≥ 4 mg/L). Seventy of 430 (16.3%) for 
which data on betalactamase production was available 
were betalactamase positive and thus expressed high-
level plasmid-mediated resistance to penicillin. High-
level resistance to azithromycin (≥ 256 mg/L) was not 
detected.
N. gonorrhoeae isolates from female patients (n = 107) 
were more resistant to penicillin (33.6%, 95% CI: 25.4–
43.0% vs 23.2%, 95% CI: 19.0–28.1%; p = 0.041) and 
ciprofloxacin (78.5%, 95% CI: 69.7–85.3% vs 68.2% 
95% CI: 63.0–73.0; p = 0.0499) than isolates from male 
patients (n = 327). There was no difference regarding 
resistance to azithromycin or tetracycline (data not 
shown). Patients older than 25 years (n = 317) and those 
aged 25 years or younger (n = 117) did not differ regard-
ing resistance to penicillin (p = 0.536), azithromycin 
(p = 0.481), ciprofloxacin (p = 0.478) or tetracycline 
(p = 0.450).
Comparison of antimicrobial resistance 2004–
2009 vs 2010–2015
Demographic data of the two subpopulations, patients 
whose isolates were analysed in 2004–2009 and those 
whose isolates were analysed 2010–2015, were com-
parable (Table 2). Applying the EUCAST definitions for 
resistance [15], the proportion of isolates resistant to 
tetracycline significantly increased and in fact almost 
doubled (2004–2009, 30.4%; 2010–2015, 55.6%; Table 
3). There also was a trend (p = 0.084) towards increas-
ing resistance to azithromycin (2004–2009, 3.0%; 
2010–2015, 7.1%; Table 3) while the resistance to 
penicillin or ciprofloxacin did not change significantly 
within the study period. A more detailed analysis by 
plotting the data for two-year periods confirmed this 
overall pattern for the whole study period (tetracycline, 
p = 0.006; penicillin, p = 0.411; ciprofloxacin, p = 0.844; 
azithromycin, p = 0.133; Figure 1); notably, resistance to 
ciprofloxacin increased between 2004/05 and 2008/09 
but decreased thereafter (p < 0.0001, each).
Analysis of the individual MICs of the seven antibiot-
ics tested revealed some minor changes for most anti-
biotics (Figure 2). In contrast, proportions of isolates 
with MICs of 0.5 or 1 mg/L to tetracycline decreased 
considerably while those of isolates with MICs of 2, 
4 or ≥32 mg/L increased (Figure 2F). Likewise, the 
increase in isolates with MICs > 0.5 mg/L to azithromy-
cin became evident but the proportions of isolates with 
MICs of 0.125 and 0.25 mg/L were rather higher in the 
second period than before (Figure 2D). The unique pat-
tern of ciprofloxacin revealed two groups of isolates, 
i.e. one expressing very low MICs and the other one 
with MICs ≥ 0.5 mg/L while there were almost no iso-
lates with MICs at the level of the EUCAST breakpoint 
concentration, 0.06 mg/L, or slightly higher or lower 
(Figure 2E). Notably, there was a stable pattern for 
both cefixime and ceftriaxone, excluding also potential 
shifts of MICs at lower concentrations (Figure 2B and 
C), which might go undetected when only the break-
points are considered. 
Discussion
Although we were unable to detect cephalosporin-
resistant N. gonorrhoeae isolates within the study 
Table 1
Antimicrobial activities of selected antibiotics against Neisseria gonorrhoeae isolates, Stuttgart, 2004–2015 (n=434)
MIC (mg/L) % of isolates (S/I/R*)
Antimicrobial agent MIC50 MIC90 Range EUCAST [8] CLSI [9]
Penicillin G 0.5 8 0.002 to >32 9.4/65.0/25.6 9.4/65.0/25.6
Cefixime 0.016 0.03 <0.016 to 0.125 100/NM/0 100/ NM /0
Ceftriaxonea 0.008 0.03 <0.002 to 0.125 100/NM/0 100/NM/0
Azithromycin 0.25 0.5 0.016 to 128 73.5/21.0/5.5 n.d.
Ciprofloxacin 2 32 <0.002 to >32 29.5/0.2/70.3 29.7/5.8/64.5
Tetracycline 2 32 0.016 to >256 31.1/20.5/48.4 17.3/34.3/48.4
Spectinomycin 8 16 1 to 32 100/NM/0 100/NM/0
CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; I: intermediate; MIC: 
minimum inhibitory concentrations; n.d.: not determined (no breakpoints available); NM: no MICs for intermediate susceptibility defined; R: 
resistant; S: susceptible. 
a Data available for 432 isolates.
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period, cefixime resistance has been reported for 
many European countries including Germany [8]. Thus, 
our data, although in line with two recently published 
German studies [9,10], cannot be considered repre-
sentative for the situation in Germany, but they indi-
cate that the true overall cefixime resistance rate in 
Germany may be considerably lower than the 10.2% 
reported for 2011 by EURO-GASP [8]. In fact, all labora-
tory results may strongly depend on the area where the 
samples were collected and the numbers of patients 
included from high-risk groups. Our key finding in this 
context, however, is the absence of an increase in MICs 
to cephalosporins from the period 2004–2009 to the 
period 2010–2015 (Figure 1). Thus, a possible rise in 
cephalosporin-resistance in the future may not be the 
result of previous and current (mis-)usage of cefixime 
in the local population, but rather due to the introduc-
tion of new resistant strains into that population.
The EUCAST breakpoint of cefixime may be too high, 
as N. gonorrhoeae isolates with this or lower MICs 
have been described as the cause of infections that 
did not resolve under cefixime standard therapy [8]. 
Considering a breakpoint of 0.06 mg/L, seven isolates 
(1.6%) tested by us with a MIC of 0.125 mg/L were 
resistant to cefixime.
We detected azithromycin resistance in 5.5% of the 
isolates and none of the isolates expressed high-
level resistance; both findings correspond to the data 
recently published by Horn et al. [10]. In contrast, an 
azithromycin resistance rate of 0.9% has been reported 
for Germany by EURO-GASP [8]. Notably, we observed 
a strong trend towards more isolates with MICs > 0.5 
mg/L of azithromycin from the period 2004–2009 to 
2010–2015 (p = 0.084), although in Europe, resistance 
significantly decreased between 2009 and 2011 [8]. 
Still, increasing azithromycin high-level resistance of 
N. gonorrhoeae isolates and a concomitant decline 
in isolates expressing decreased susceptibility have 
been shown for Scotland from 2004 to 2007 [17] from 
where it appears to have spread to England and Wales 
[18]. Only single high-level resistant isolates have 
been shown for other European countries, including 
Italy [19], Sweden [20], France [21] and Ireland [22]. To 
prevent further increasing resistance to this valuable 
drug, azithromycin usage should be limited to patients 
who need to be treated with this drug, i.e. patients 
with allergy to cephalosporins or patients with simul-
taneous chlamydial infection (in which case azithromy-
cin should be given together with cephalosporins) and 
those for whom no drug susceptibility testing of the 
causative agents can be performed.
Table 2
Demographic data from Neisseria gonorrhoeae-positive patients, south-west Germany, 2004–2009 vs 2010–2015 (n=414)
Characteristics July 2004 to December 2009 January 2010 to March 2015 p-value
Number of isolates 168 266
Sex 0.909
Female 42 (25.0%) 65 (24.4%)
Male 126 (75.0%) 201 (75.6)
Age in years (median; range) 32; 17-68 34; 16-76 0.718
Specialisation of senders
Urology 78 (47.0%) 149 (56.0%) 0.076
Gynaecology 37 (22.3%) 61 (22.9%) 0.906
Internal medicine 20 (12.0%) 22 (8.3%) 0.235
Dermatology 16 (9.6%) 20 (7.5%) 0.479
Others or no specialisation 15 (9.0%) 14 (5.3%) 0.167
Table 3
Resistance of Neisseria gonorrhoeae isolates, south-west Germany, 2004–2009 vs 2010–2015 (n=434)
2004–2009 (n=168) 2010–2015 (n=266)
Antibiotic agent No % (95% CI) a No % (95% CI) p 
Penicillin G (>1 mg/L) 42 25.0 (19.0-32.1) 69 25.9 (21.0-31.5) 0.910
Azithromycin (>0.5 mg/L) 5 3.0 (1.1-7.0) 19 7.1 (4.6-10.9) 0.084
Ciprofloxacin (>0.06 mg/L) 111 66.1 (58.6-72.8) 194 72.9 (67.3-77.9) 0.133
Tetracycline (>1 mg/L) 62 36.9 (30.0-44.4) 148 55.6 (49.6-61.5) 0.0002
CI: confidence interval.
a Percentage of resistant isolates defined by European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints plus 95% CI.
6 www.eurosurveillance.org
The highest resistance rate was observed for cipro-
floxacin (70.3%). This is in accordance with the data 
published by Horn et al. [10] while resistance rates of 
around 50% have been reported by others for Germany 
[8,9]. Resistance rates for ciprofloxacin are also high 
in most other European countries [8], and this might 
be a sign of a still high fluoroquinolone usage by prac-
titioners for the empirical treatment of gonorrhoeae, 
as ciprofloxacin resistance of N. gonorrhoeae has 
been shown to decline after cessation of ciprofloxacin 
usage [23]. It remains unclear at the moment, however, 
whether the observed increase and decrease of cipro-
floxacin resistance correlates with changes in cipro-
floxacin usage within the study period. In contrast to 
the other antimicrobials tested, MICs to ciprofloxacin 
showed a bimodal distribution similar to what has been 
shown for N. gonorrhoeae isolates from Japan [24].
Tetracycline resistance also was high (as previously 
observed by others [10]), and increased significantly 
within the study period (from 27.5% in 2004/2005 to 
57.7% in 2014/2015). This might reflect its wide usage. 
Doxycyline was the second most commonly prescribed 
antimicrobial drug in German outpatient departments 
in 2011 [25]. When we compared the antimicrobial sus-
ceptibility for 2004–2009 vs 2010–2015, considerably 
more isolates were included in the latter than in the 
former period, although the second period was three 
months shorter than the earlier one. Even if it must 
remain speculative at the moment, this finding might 
indicate a true increase in cases of gonorrhoea in 
the past years, similar to what has been reported for 
England and Sweden [26,27], and thus may correspond 
to the trend reported for syphilis in Germany [28]. A 
reintroduction of the previous obligation to report all 
cases of gonorrhoea in Germany, currently under dis-
cussion, may answer this question in the future. An 
increasing gonorrhoea incidence, however, also might 
at least partially result from the previously discussed 
ciprofloxacin usage for empirical treatment of the 
infection in the presence of high resistance rates to 
this drug [29].
We did not detect spectinomycin resistance. This might 
be due to its long-lasting non-usage, since its usage 
leads to increasing resistance rates [30]. Thus, this 
drug could potentially be used for the empirical treat-
ment of gonorrhoea. Known limitations, however, are 
its unavailability in many European countries including 
Germany and its reduced effectiveness in the treat-
ment of pharyngeal gonorrhoea [31].
In contrast to previous publications [13,14], we did 
not observe age-related differences in susceptibil-
ity rates, and isolates from female patients showed 
higher resistance rates than those from male patients. 
This might be due to differences in study populations. 
One limitation of our study in this context is the fact 
that we do not have information regarding patients 
who may belong to high-risk populations. For instance, 
it has been shown that N. gonorrhoeae isolates from 
MSM are more resistant to antimicrobials than those 
collected from men who have sex with women [32,33]. 
Likewise, infected commercial sex workers are more 
likely to harbour resistant N. gonorrhoeae isolates than 
other patients [32,34]. In contrast, a recent EURO-GASP 
study has demonstrated decreasing cefixime MICs for 
N. gonorrhoeae of MSM for the period 2009–2011, and 
highest MICs for isolates from men who have sex with 
women [13]. Furthermore, around 75% of the bacterial 
isolates analysed in the present study were collected 
from men; thus, our data may be more valid for male 
than for female patients.
In conclusion, the current resistance situation of N. 
gonorrhoeae isolates in south-west Germany may be 
less dramatic than in other parts of Germany or other 
European countries. High resistance rates to some 
antimicrobials and changes of susceptibility over time, 
however, call for a more stringent monitoring system, 
e.g. the obligation of every laboratory to report all N. 
gonorrhoeae isolates together with their susceptibility 
testing results.
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